KeyBanc Capital Markets maintained its Overweight rating and $274.00 price target on ResMed (NYSE ... This article was generated with the support of AI and reviewed by an editor.

ResMed Inc.’s RMD growth in the third quarter of fiscal 2025 can be attributed to the robust performance of its Mask business. Its progress in digital health technology continues to drive ...

CHAT offers focused exposure to the GenAI ecosystem, but concentration and sector risk are inherent to its thematic strategy. Portfolio holdings support CHAT for long-term AI growth, but recent ...

Sleep and respiratory disorders sector of the medical device industry ("Sleep and Respiratory Care') and the supply of business management software as a service to out-of-hospital health providers ...

Farrell sold 8,009 shares of ResMed common stock at a weighted average price of $251.21 per share, totaling approximately $2.01 million. This transaction was conducted under a pre-established Rule ...

YARMOUTH, Maine – CPAP providers say they can’t fault Resmed for expanding its reach into the sleep market, but there’s always concern that a “Goliath” will eventually muscle smaller companies out of ...

Despite this, they maintain a positive outlook on ResMed’s stock, reaffirming their Buy rating. The company’s solid revenue growth of 9.54% and strong market position support this positive outlook. In ...